Exclusive: HRSA Asking Hospitals About 340B Patient Definition, 340B Savings, and Using 340B at Child Sites

Dept. of Health and Human Services building and signage
Hospital advocates said HRSA's recent decision to end a 340B program waiver for hospitals could draw legal challenges.

UPDATED Thursday March 2, 2023, 12:30 p.m. EDT to include comment from HRSA.

The U.S. Health Resources and Services Administration has asked multiple hospitals to explain how they determine patient eligibility for 340B drugs, how they define, track, and use

Read More »

Feds Considering Asking Full Appeals Court to Rehear Case Over AstraZeneca, Novo Nordisk, and Sanofi’s 340B Contract Pharmacy Policies

Seal of the U.S. Court of Appeals for the Third Circuit
HHS might ask the full U.S. Third Circuit Court of Appeals to rehear a a lawsuit over AstraZeneca, Novo Nordisk, and Sanofi’s 340B contract pharmacy policies.

The federal government may ask all 14 judges on the U.S. Third Circuit Court of Appeals to review a three-judge panel’s unanimous January opinion upholding AstraZeneca, Novo Nordisk, and Sanofi’s restrictions on 340B pricing when their drugs are shipped to

Read More »

Senate Democratic Whip Durbin: 340B Hasn’t Cut Pharma Profits Dramatically

Sen. Dick Durbin (D-IL)
340B "hasn’t really cut the profits of the pharmaceutical companies dramatically,” U.S. Senate Majority Whip Dick Durbin (D-Ill.) said during a visit to a Chicago community health center.

The 340B program “is a really successful program and it hasn’t really cut the profits of the pharmaceutical companies dramatically,” U.S. Senate Majority Whip Dick Durbin (D-Ill.) said Friday during a visit to a Chicago-based community health center.

Durbin is

Read More »

Judge Pauses PhRMA’s 340B Administrative Dispute Resolution Lawsuit

US District courthouse and signage in Baltimore, MD
A federal district judge in Baltimore has paused PhRMA's lawsuit challenging the current 340B program administrative dispute resolution process.

A federal district judge in Baltimore, Md., yesterday stayed the brand drug industry’s lawsuit challenging the December 2020 340B program administrative dispute resolution final rule.

Lawyers for Pharmaceutical Research and Manufacturers of America and U.S. Health and Human Services Secretary

Read More »

340B Report Publisher and CEO: Is Hospital Transparency the Key to a Grand Bargain on 340B?

Handshake over table
Could hospitals' acceptance of 340B reporting requirements help end the fight over limits on 340B contract pharmacy and encroachment on providers’ 340B savings, 340B Report Publisher and CEO Ted Slafsky asks.

Could ending the fights over limits on 340B contract pharmacy and encroachment on providers’ 340B savings hinge on hospitals accepting 340B reporting requirements? 340B Report Publisher and CEO Ted Slafsky raises that provocative question in his monthly column for Verity

Read More »

One-Third of Americans Lack a Source of Primary Care and Health Centers Can Close the Gap, Says Report

Map of United States depicting percentages of medically disenfranchised populations
Almost one-third of Americans lack access to a usual source of primary care, the National Association of Community Health Centers says in a new report.

More than 100 million Americans—almost one-third of the population, and many of them children—lack access to a usual source of primary care due to a shortage of providers in their community, leading to delays in care, poorer health outcomes, and

Read More »

Key Lawmaker Introduces Bill to Protect NY Health Centers and Clinics from “Hundreds of Millions” in Lost 340B Savings

New York state capitol building and plaza
A bill has been introduced in New York State to repeal the April 1 shift of state Medicaid managed care pharmacy benefits to Medicaid fee for service.

The chair of the New York Senate health committee has introduced legislation to repeal the April 1 shift of state Medicaid managed care pharmacy benefits to Medicaid fee for service. The state’s 340B health centers and Ryan White clinics say

Read More »

Study Raises Questions About Using 340B Claim Modifiers to Implement Medicare Drug Price Negotiation and Inflation Rebate Provisions

IQVIA white paper title page
IQVIA questions whether 340B claims identifiers can be used successfully to implement the Inflation Reduction Act's Medicare drug price negotiation and drug inflation rebate provisions.

New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and a 340B

Read More »

America’s Essential Hospitals Asks HHS to Swiftly Repay 340B Hospitals for Unlawful Medicare Drug Payment Cuts

America's Essential Hospitals wordmark and tagline
America’s Essential Hospitals wants HHS “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B hospitals under Medicare Part B.”

America’s Essential Hospitals asked U.S. Health and Human Services Secretary Xavier Becerra late last week “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B
hospitals under Medicare Part B.”

“These cuts, and a delay in recompensing hospitals for

Read More »

J&J Announces Major Expansion of 340B Contract Pharmacy Limits; Pushback Is Likely

Johnson & Johnson signage in front of building
Johnson & Johnson is poised to become the first drug maker to place a condition on 340B sales and deliveries to covered entity in-house pharmacies.

Johnson & Johnson, the world’s biggest drug company, yesterday announced a major expansion of the drug industry’s campaign to set limits on 340B drug sales.

On March 7, it is poised to become the first drug maker to place a

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live